scispace - formally typeset
Open AccessJournal ArticleDOI

Adaptogenic and central nervous system effects of single doses of 3% rosavin and 1% salidroside Rhodiola rosea L. extract in mice

Marina Perfumi, +1 more
- 01 Jan 2007 - 
- Vol. 21, Iss: 1, pp 37-43
Reads0
Chats0
TLDR
Evidence of the efficacy of R. rosea extracts after a single administration is provided, and many preclinical and clinical studies indicating the adaptogenic and stimulating effects of such R.rosea extracts are confirmed, as antidepressant‐like and anxiolytic‐like activities of R.'s rosea were shown for the first time.
Abstract
Rhodiola rosea L., or 'golden root', is a popular plant in traditional medicine in Eastern Europe and Asia, with a reputation for improving depression, enhancing work performance, eliminating fatigue and treating symptoms of asthenia subsequent to intense physical and psychological stress. Due to these therapeutic properties, R. rosea is considered to be one of the most active adaptogenic drugs. To confirm and extend results obtained in the few preclinical and clinical studies available in English language journals, the purpose of the present study was to re-investigate the effects produced by a single oral administration of an R. rosea hydroalcohol extract (containing 3% rosavin and 1% salidroside) on the central nervous system in mice. The extract was tested on antidepressant, adaptogenic, anxiolytic, nociceptive and locomotor activities at doses of 10, 15 and 20 mg/kg, using predictive behavioural tests and animal models. The results show that this R. rosea extract significantly, but not dose-dependently, induced antidepressant-like, adaptogenic, anxiolytic-like and stimulating effects in mice. This study thus provides evidence of the efficacy of R. rosea extracts after a single administration, and confirms many preclinical and clinical studies indicating the adaptogenic and stimulating effects of such R. rosea extracts. Moreover, antidepressant-like and anxiolytic-like activities of R. rosea were shown in mice for the first time.

read more

Citations
More filters
Journal ArticleDOI

Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy.

TL;DR: Rhodiola rosea has robust traditional and pharmacological evidence of use in fatigue, and emerging evidence supporting cognition and mood, and it potentially attractive for use as a safe medication.
Journal ArticleDOI

Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence

TL;DR: A review of the literature was conducted to ascertain mechanisms of action of these botanicals, in addition to a systematic review of controlled clinical trials for treatment of mood, anxiety and sleep disorders, which are common comorbid psychiatric disorders.
Journal ArticleDOI

Feeding and reward: perspectives from three rat models of binge eating.

TL;DR: Data derived from three selected animal models of normal-weight non-homeostatic feeding behavior that have been significantly influenced by Bart Hoebel's 40+-yr career show that behavioral and neuronal consequences of bingeing on a palatable food, even when at a normal body weight, are different from those that result from simply consuming the palatableFood in a non-binge manner.
Journal ArticleDOI

Medicinal plants of the Russian Pharmacopoeia; their history and applications.

TL;DR: The review highlights the therapeutic potential of these Russian phytopharmaceuticals but also highlights cases where concern has been raised about product safety and tolerability, which would aid in supporting their safe use.
Journal ArticleDOI

Monoamine oxidase inhibition by Rhodiola rosea L. roots.

TL;DR: The present investigation demonstrates that Rhodiola rosea L. roots have potent anti-depressant activity by inhibiting MAO A and may also find application in the control of senile dementia by their inhibition of MAO B.
References
More filters
Journal ArticleDOI

Depression: a new animal model sensitive to antidepressant treatments

R D Porsolt, +2 more
- 21 Apr 1977 - 
TL;DR: Results presented below indicate that immobility is reduced by different treatments known to be therapeutic in depression including three drugs, iprindole, mianserin and viloxazine which although clinically active show little or no ‘antidepressant’ activity in the usual animal tests.
Journal Article

Behavioral despair in mice: a primary screening test for antidepressants

TL;DR: The mouse procedure is more rapid and less costly than that with rats and is thus more suitable for the primary screening of antidepressant drugs, suggesting that the procedure is selectively sensitive to antidepressant treatments.
Journal ArticleDOI

The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review

TL;DR: Compounds that have a different spectrum of therapeutic efficacy in anxiety disorders such as panic attacks, generalized anxiety disorder or obsessive-compulsive disorder were poorly effective as anxiolytics in the open field test, suggesting that this paradigm may not model features of anxiety disorders.
Journal ArticleDOI

The Open-Field Test: a critical review.

TL;DR: Over the w t 4 0 years Lhc open field bar ~ o l v e d a a commonly used tool for the rnmumcnt of animal behavior ~ a dtical look at the the authors of instrument, with regard to the development of a standard form for iu w.
Journal ArticleDOI

Assessing antidepressant activity in rodents: recent developments and future needs

TL;DR: This review focuses on recent findings regarding some of the most widely employed animal models used currently to predict antidepressant potential, and emphasis is placed on recent modifications to such paradigms that have increased their utility and reliability.
Related Papers (5)